Healthcare entity
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Grünenthal Group, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention NaV 1.8 inhibitor, all published on February 19, 2026.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Grünenthal Group, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention NaV 1.8 inhibitor, all published on February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NaV 1.8 inhibitor. Shared-story counts are live from our verified record — not editorial picks.
Grünenthal Group has initiated clinical development for its proprietary NaV 1.8 inhibitor, a major step toward providing a non-opioid alternative for pain management. This move positions the German pain specialist as a key competitor in the high-growth peripheral sodium channel inhibitor market.
Source: finanznachrichten.de · prleap.com
NaV 1.8 inhibitor is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
